WAY-322243

CAS No. 332939-32-9

WAY-322243( —— )

Catalog No. M36995 CAS No. 332939-32-9

WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 33 In Stock
5MG 51 In Stock
10MG 84 In Stock
25MG 177 In Stock
50MG 259 In Stock
100MG 393 In Stock
200MG Get Quote In Stock
500MG 890 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WAY-322243
  • Note
    Research use only, not for human use.
  • Brief Description
    WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.
  • Description
    WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    332939-32-9
  • Formula Weight
    326.41
  • Molecular Formula
    C18H18N2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(NC(CCC)=O)(C1=C(O)C2=C(C=C1)C=CC=N2)C3=CC=CS3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CDK12-IN-5

    CDK12-IN-5 is a potent CDK12 inhibitor with potential anticancer and antitumor activity, and can be used orally in the study of breast and ovarian cancer.

  • Atuveciclib

    Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1.

  • AZA197

    AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.